Home » GTC Biotherapeutics and LFB Biotechnologies Developing CD20 Antibody
GTC Biotherapeutics and LFB Biotechnologies Developing CD20 Antibody
GTC Biotherapeutics, Inc. and LFB Biotechnologies, a wholly owned subsidiary of LFB S.A. (Laboratoire francais du Fractionnement et des Biotechnologies S.A.), announced that they have initiated development of a transgenically produced CD20 monoclonal antibody under the existing agreement between GTC and LFB Biotechnologies.
GTC Biotherapeutics
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May